| ACLAX | VMVAX | ACLAX / VMVAX | |
| Total Expense Ratio | 1.22 | 0.07 | 1,743% |
| Annual Report Gross Expense Ratio | 1.22 | 0.07 | 1,743% |
| Fund Existence | 21 years | 14 years | - |
| Gain YTD | 4.805 | 6.005 | 80% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 2500 | 3000 | 83% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 6.26B | 31.8B | 20% |
| Annual Yield % from dividends | 1.28 | 2.20 | 58% |
| Returns for 1 year | -5.73 | 0.61 | -938% |
| Returns for 3 years | 1.32 | 24.49 | 5% |
| Returns for 5 years | 3.67 | 50.99 | 7% |
| Returns for 10 years | 9.67 | 97.41 | 10% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CSHCX | 8.36 | 0.01 | +0.12% |
| NYLI Cushing® MLP Premier Class C | |||
| PMVAX | 20.07 | 0.01 | +0.05% |
| Putnam Sustainable Future A | |||
| VMGIX | 108.18 | N/A | N/A |
| Vanguard Mid-Cap Growth Index Investor | |||
| TNYRX | 10.74 | N/A | N/A |
| 1290 Loomis Sayles Multi-Asset Income R | |||
| RSECX | 17.60 | -0.13 | -0.73% |
| Russell Inv US Strategic Equity C | |||